Tranham Partners

Executive search  /  New York  /  London

We know everyone you're about to hire.

Tranham Partners finds senior leaders for private equity investors in US healthcare, and investment professionals for US real estate investors. We work in those two markets only. Our healthcare practice alone knows more than 1,200 executives across the country, so when you call, we're ranking people we've already met.

Practice 01

Private Equity

CEOs, CFOs and C-suite leaders for PE-backed healthcare, from SaaS and services to life sciences and insurance.

Portfolio companies mapped1~2,000
Executives known, across the US21,200+
Shortlist standard37 days
Private equity practice

Practice 02

Real Estate

Investment professionals, analyst to managing director, for US real estate equity and credit investors.

Investment firms worked with420+
Client assets under management4$1B–$100B+
Shortlist standard37 days
Real estate practice

How we work

Five rules we hold ourselves to, in both practices.

  1. We work in two markets only.

    PE-backed healthcare, from SaaS and services to clinical research, manufacturing and insurance, and US real estate investment. We don't take mandates outside them.

  2. We know the people before the search.

    We track executives for years before they're needed: where they sit, what they've delivered and when they're likely to move. A search starts with people we've already met.

  3. We move in days.

    A shortlist within 7 days of a signed engagement letter. We aim for an accepted offer within six to eight weeks.3

  4. We check every claim.

    Exits, multiples, deal volume, sponsors and revenue are each tested against a second source. You see which we could confirm and which we couldn't.

  5. Your portfolio is off-limits.

    We don't recruit out of the businesses we serve. Working with us never puts your own leadership at risk.

The scouting report

Every candidate we present comes with one: the evidence behind each claim, and how far we could confirm it.

Candidate 0417 · anonymized

Chief Financial Officer, multi-site dental platform

Southeast US · sponsor-backed · 71 locations

5/6signals verified
SignalEvidenceStatus
Exits & multiplesTwo sponsor exits, best at 12.5x EBITDAVerified
Big-4 or IB trainingAudit, Big-4, six yearsVerified
CPAActive licenseVerified
Sub-sector & scaleDental, $150–250M revenue bandVerified
Value creation9 add-ons integrated, 14 de novosInferred
Sponsors, availabilityTwo credible sponsors; 90-day noticeVerified
Revenue
$62M to $180M
EBITDA
$9M to $31M
Locations
24 to 71

Samples, not real people. Client shortlists are anonymized the same way until both sides agree to meet.

Practice 01

Private Equity

We place the leaders who grow PE-backed US healthcare companies and get them sold: in SaaS and tech-enabled services, care delivery, clinical research, manufacturing and insurance. Our clients invest in the lower-middle and middle market: platforms from $20M to $600M of revenue, most of them building from $1–10M of EBITDA toward $40–50M.

Where we add value

Pre-deal
Operators who can underwrite a thesis with you, and a CEO or CFO lined up before you sign the LOI.
Diligence
An outside read on the management team you're inheriting, and the seats you'll need to fill.
Confirmations
Reference checks on and off the candidate's list, with their consent. Every exit, multiple and EBITDA figure tested against a second source.
Post-close
The CFO first, then the team around them: finance, operations, commercial and marketing leaders. Operating partners and board seats.
Exit
CFOs who have already been through a buyer's quality of earnings review.

Healthcare SaaS and tech-enabled services

  • Healthcare SaaS
  • Healthcare IT
  • Tech-enabled services
  • Revenue cycle management

Payors and insurance

  • Third-party administrators (TPAs)
  • Insurers
  • Alternative healthcare insurance markets
  • Payor services

Healthcare services

  • ABA and behavioral health
  • Dental
  • Multi-site physical therapy
  • Orthopedics and MSK

Specialty and home-based care

  • Infusion
  • Home health and hospice
  • Dermatology
  • Provider services

Clinical research and labs

  • Clinical trials
  • Contract research organizations (CROs)
  • Site networks
  • Lab testing

Manufacturing

  • Medical devices
  • Healthcare manufacturing
  • Pharmaceutical manufacturing
  • CDMOs
Seats
CEO, CFO and the finance team, COO and operations, commercial and marketing leadership, operating partner, independent director, audit committee chair.

Practice 02

Real Estate

We place the investment professionals who source, finance and manage US real estate, for equity and credit investors. Our clients manage from $1B to more than $100B of assets.4

Where we add value

Launch
The first investment hires for a new strategy, fund or US market entry.
Diligence
An assessment of the platform team you're buying, and who you'd need around them.
Confirmations
Deal-by-deal checks of a candidate's track record: volume closed, capital raised and returns, with the source of each noted.
Post-close
Team builds across acquisitions, originations, asset management and capital markets.
Capital raise
Capital raising and investor relations hires in place before the next fund goes out.

Clients

  • Real estate private equity
  • Real estate private credit
  • Fund and investment managers
  • Asset management firms
  • Developers
  • Owner-operators
  • REITs
  • Family offices

Asset classes

  • Multifamily
  • Industrial and logistics
  • Office
  • Hospitality
  • Data centers and life science
  • Student and senior housing
  • Single-family rental
  • Retail

Functions

  • Acquisitions
  • Originations
  • Asset management
  • Portfolio management
  • Development
  • Capital markets
  • Capital raising
  • Investor relations
Seats
Analyst to Managing Director, across every function above.

People

Each practice is run by a partner who works only in that market. Between them, our partners have completed more than 70 searches.5

David Tran

David Tran

Co-founder & Partner, Private Equity · New York

David leads the private equity practice. He trained at Levin Group and Gresham Executive and has completed 26 searches across his career, placing CEOs and CFOs as well as operations, commercial and marketing leaders. He built the firm's healthcare market map and works with sponsors from pre-deal through exit.

david.tran@tranhampartners.com

Maximilian Fillingham

Maximilian Fillingham

Co-founder & Partner, Real Estate · London

Maximilian leads the real estate practice. He works with US investors, lenders, developers and operators, placing professionals in originations, acquisitions, debt and equity asset management and capital markets.

max.fillingham@tranhampartners.com

Give us one week, and you'll never have to worry about hiring again.

Start a search

Ways to engage

Retained search
One seat, one dedicated search. A market map, a shortlist within a week, reference checks and support through the offer.
Executive networking retainer
For investors who are always buying. A few strong introductions every two or three weeks in the areas you're targeting, so you have a bench before you have a vacancy.
Pre-deal and diligence advisory
Management assessment, operator introductions and reference checks on a live deal, scoped to your timetable.

The market, as we see it

Sources dated February 2025 to September 2026. Notes at the foot of the page.

Private Equity · healthcare and finance leadership

1,153

US healthcare PE deals in 2025, worth $138.5B.6

2.5 yrs

average tenure of a portfolio-company CFO, across sectors.7

1 in 2

PE-backed CFOs surveyed had been in the seat two years or less.8

6 yrs

median hold at exit, all US buyouts.6

Holding period and CFO tenure, years
Median hold at exit, US buyouts66.0
Public-company CFO, average tenure75.6
Portfolio-company CFO, average tenure72.5

Our view

A portfolio CFO lasts 2.5 years on average,7 against a six-year median hold.6 Over a hold that long, expect to replace the CFO at least once. Sponsors who have already met their next CFO make that change on their own timetable.

Real Estate · capital and leadership

$875B

of US commercial and multifamily mortgages mature in 2026, 17% of the $5.0T outstanding.9

38%

of CBRE's non-agency loan closings went to alternative lenders in Q2 2026, up from 34% a year earlier.10

21%

year-over-year rise in US commercial real estate investment in H1 2026, to $250.3B.11

59%

of US CRE leaders reach retirement age within a decade, Deloitte estimates.12

Commercial and multifamily mortgages maturing, $B
2025 (as scheduled)9957
20269875
20279652

Our view

Investment volume is rising again11 and alternative lenders are taking a larger share of loan closings.10 With $875B of loans maturing in 2026 and $652B in 2027,9 demand is moving toward originators, credit underwriters and asset managers. Only 30% of the executives Deloitte surveyed say their firm is very prepared for C-suite transitions,12 which makes succession a search question.

Tell us about the seat.

The role, the business, the timing. We'll come back within one business day with a straight read on the market and how fast we can move.

info@tranhampartners.com

447 Broadway, 2nd Floor
New York, NY 10013

We use these details only to respond to your inquiry. See our privacy policy.

How we count

  1. Portfolio companies mapped. Active PE-backed US healthcare portfolio companies in Tranham's market map, built from licensed deal databases and public deal announcements. No single published count exists; this is our count, as of October 2026. ↩
  2. Executives known. PE-backed healthcare executives across the US, mostly CFOs and finance leaders, whom a Tranham partner has spoken with directly and who hold a verified record in our database. As of October 2026. ↩
  3. Shortlist standard. Our service standard in both practices: calendar days from a signed engagement letter to the first shortlist. We aim for an accepted offer within six to eight weeks and reply to new inquiries within one business day. ↩
  4. Real estate figures. Investment firms worked with on real estate searches, and the range of their assets under management. As of October 2026. ↩
  5. Searches completed. Searches completed by Tranham's two partners across their careers, including at previous firms. As of October 2026. ↩

Executive records are re-checked against company leadership pages, press releases and deal announcements on a rolling basis. We only record a move when two independent public sources agree. Every claim in a scouting report is marked verified, inferred or unknown, and we never present an unknown as fact.

Sources

  1. PitchBook, 2025 Annual US PE Breakdown, data as of December 31, 2025. Healthcare deal count and value; median holding period at exit (all US buyouts). ↩
  2. Russell Reynolds Associates, How to Attract and Retain Portfolio CFOs in a Competitive Market, February 2025. Study of 150 portfolio companies of 17 US mid-cap to mega-cap sponsors, across sectors. Public-company figure is the average tenure of outgoing public-company CFOs. ↩
  3. Heidrick & Struggles, 2025 PE-Backed CFO Compensation Survey, April 2026. 213 US respondents across sectors. ↩
  4. Mortgage Bankers Association, 2025 Commercial Real Estate Survey of Loan Maturity Volumes, released February 9, 2026. Commercial and multifamily mortgages; balances as of December 31, 2025. The 2025 figure is the amount scheduled to mature in 2025, as cited in the same release. ↩
  5. CBRE, Commercial Real Estate Lending Fundamentals Remain Strong in Q2 2026, August 3, 2026. ↩
  6. CBRE, Q2 2026 U.S. Capital Markets Report, July 30, 2026. ↩
  7. Deloitte, 2027 Commercial Real Estate Outlook, September 24, 2026. The 59% is Deloitte's estimate for US CRE leadership; the 30% comes from its survey of 950 C-level executives and their direct reports at CRE owners and investment companies with at least $250M of assets under management. ↩